Page 16 - Slide 1
P. 16
Amgen Bone Health Mentoring Program
Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN
1065 LLP2A-Alendronate, a Novel Anabolic Treatment to
Reverse Bone Loss.
Yao W, Guan M, Jia J, et al.
Session: Concurrent Oral Session 11: Osteoporosis -
Treatment (Preclinical) ◼ Saturday , October 13, 03:15
PM - 03:30 PM◼ Auditorium Room 3/Minneapolis
Convention Center
Background/ Abstract Information Additional Notes from
Objective Poster/Presentation*
▪ Previous studies have indicated that
Methods LLP2A, a synthetic peptidomimetic ligand Strengths,
increases MSC migration and commitment Weaknesses, Key
of MSCs to osteoblast differentiation in Points
vitro; in vivo it is known to increase bone
formation and bone mass in mice.
▪ This study evaluated the effects of LLP2A-
Ale, with or without the MSC
transplantation, in C57BL/6 female mice
with bone loss induced by ovariectomy or
advanced aging.
▪ The report consists of data from 3 efficacy
studies
o The first study used 10-week-old
ovariectomized mice with established
bone loss.
o The second study used 24-week-old
adult mice.
o Third study used 24-month-old aged
mice.
▪ LLP2A-Ale was given as a two monthly
dose (0.9nmol IV) or in combination of
mouse MSC (IV 5 x 105).
* Assignment notes will be collected at the Amgen Mentoring Program Debrief Meeting. Hardcopy or Electronic versions are acceptable
